Evidence map›Paper›PMID 25300360›Full record

ArticleScientific reports2014

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies.

Yow-Wen Hsieh, Ching-Ya Huang, Shih-Ying Yang, Yu-Hsuan Peng, Chung-Ping Yu, Pei-Dawn Lee Chao, Yu-Chi Hou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 59 citations in OpenAlex.

  1. Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yow-Wen Hsieh1] School of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C. [2] Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404, R.O.C.
Ching-Ya Huang1] School of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C. [2] Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404, R.O.C.
Shih-Ying YangSchool of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C.
Yu-Hsuan PengSchool of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C.
Chung-Ping YuSchool of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C.
Pei-Dawn Lee ChaoSchool of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C.
Yu-Chi Hou1] School of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C. [2] Department of Medical Research, China Medical University Hospital, Taichung, Taiwan 404, R.O.C.
China Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin, a specific secondary metabolite of Curcuma species, has potentials for a variety of beneficial health effects. It is nowadays used as a dietary supplement. Everolimus (EVL) is an immunosuppressant indicated for allograft rejection and cancer therapy, but with narrow therapeutic window. EVL is a substrate of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4). This study investigated the effect of coadministration of curcumin on the pharmacokinetics of EVL in rats and the underlying mechanisms. EVL (0.5 mg/kg) was orally administered without and with 50 and 100 mg/kg of curcumin, respectively, in rats. Blood samples were collected at specific time points and EVL concentrations in blood were determined by QMS immunoassay. The underlying mechanisms were evaluated using cell model and recombinant CYP 3A4 isozyme. The results indicated that 50 and 100 mg/kg of curcumin significantly decreased the AUC0-540 of EVL by 70.6% and 71.5%, respectively, and both dosages reduced the Cmax of EVL by 76.7%. Mechanism studies revealed that CYP3A4 was markedly activated by curcumin metabolites, which apparently overrode the inhibition effects of curcumin on P-gp. In conclusion, oral intake of curcumin significantly decreased the bioavailability of EVL, a probe substrate of P-gp/CYP 3A4, mainly through marked activation on CYP 3A4.

Indexed as

Biological AvailabilityAdministration, OralAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorCurcuminCytochrome P-450 CYP3ADrug InteractionsEverolimusHumansNeoplasmsRatsSirolimusATP Binding Cassette Transporter, Subfamily B, Member 1CurcuminCytochrome P-450 CYP3AEverolimusSirolimus

Identifiers

PMID25300360
PMCPMC5377466
OpenAlexW2059339807

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.